PM 01183

01/01/2022 - "Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice."
01/01/2021 - "Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer."
01/01/2023 - "ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer."
12/01/2020 - "Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment."
06/01/2021 - "This article provides an update on available data and ongoing studies of lurbinectedin in small cell lung cancer, including Phase I combination trials, the basket Phase II trial and the ATLANTIS Phase III trial. "

06/01/2021 - "The activity of lurbinectedin has been studied in many solid tumors, showing not only promising results but also a favorable safety profile. "
06/01/2021 - "One of these treatments is a marine-derived drug called lurbinectedin, which shows promising activity in some solid tumors, such as extensive SCLC, after failure of first-line treatment. "
06/01/2021 - "However, lurbinectedin, a transcriptional inhibitor, has emerged as a potential novel treatment for cancer. "
06/01/2021 - "Here the authors present the results of the main trials related to the activity of lurbinectedin either alone or in combination with other drugs for this type of cancer."
01/01/2021 - "This study assessed the effect of lurbinectedin, a highly selective inhibitor of oncogenic transcription, on the change from baseline in Fridericia's corrected QT interval (∆QTcF) and electrocardiography (ECG) morphological patterns, and lurbinectedin concentration-∆QTcF (C-∆QTcF) relationship, in patients with advanced solid tumors. "

01/01/2022 - "This article will focus on the clinical evidence, the most recent investigations, and the future perspective regarding the use of lurbinectedin in ovarian cancer."
01/01/2022 - "Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives."
01/01/2022 - "A 44-year-old BRCA1-mutated ovarian cancer patient was treated in sixth line with lurbinectedin and irinotecan with a time to further progression (TTFP) equal to 8 months. "
01/01/2022 - "Background In vitro/in vivo data showed synergism of cisplatin and lurbinectedin in ovarian cancer cells and grafts. "
11/01/2021 - "Lurbinectedin showed similar antitumor efficacy and was better tolerated than current standard of care in patients with platinum-resistant ovarian cancer."

05/12/2021 - "Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma."
01/01/2021 - "Based on the results of a recent phase II trial, lurbinectedin has clinical activity and acceptable toxicity in the second- and third-line treatment of malignant pleural mesothelioma. "
01/01/2022 - "Lurbinectedin continues to be active in patients with progressing malignant pleural mesothelioma. "
01/01/2022 - "The SAKK 17/16 study showed promising efficacy data with lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma. "
01/01/2022 - "Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study."

10/01/2023 - "Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study."
10/01/2023 - "This phase 2 Basket trial evaluated lurbinectedin 3.2 mg/m2 1-h intravenous infusion every 3 weeks in a cohort of 73 patients with pretreated endometrial cancer. "
10/01/2023 - "Lurbinectedin showed promising antitumor activity in a phase I study in combination with doxorubicin in advanced endometrial cancer. "
11/01/2021 - "The aim of this study was to characterise the efficacy and safety of lurbinectedin and doxorubicin for patients with endometrial cancer. "
11/01/2021 - "Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study."